Thema: US64125C1099
NBIX, US64125C1099
gamestop-6286877_1920.jpg - Foto: THN
Neurocrine Biosciences stock: Q3 results set for November 2
Neurocrine Biosciences stock is heading into a scheduled results update. Management will discuss the quarter and outlook in an investor call.
ad-hoc-news.de, heute 01:42 Uhr
NBIX, US64125C1099
Needham keeps Buy target at USD 204.00 for Neurocrine Biosciences ...
Q3 results are due November 2, 2026. Neurocrine Biosciences stock costs EUR 125.40 on October 20, 2026.
ad-hoc-news.de, 20.10.26 19:30 Uhr
NBIX, US64125C1099
Needham sets USD 204.00 target for Neurocrine Biosciences ...
Results are due November 2, 2026. Neurocrine Biosciences stock cost USD 135.71 on October 16, 2026, down 0.91 percent versus Nasdaq's prior close.
ad-hoc-news.de, 17.10.26 19:47 Uhr
NBIX, US64125C1099
RBC keeps USD 187.00 target for Neurocrine Biosciences stock ...
Results arrive November 2, 2026. Neurocrine Biosciences stock costs EUR 122.23 on October 15, 2026 at 7:45 p.m. CEST, up 0.93 percent on Nasdaq.
ad-hoc-news.de, 15.10.26 19:53 Uhr
NBIX, US64125C1099
Neurocrine names Roberts CMO. Neurocrine Biosciences stock ...
Revenue reached USD 959 million in second-quarter 2026, up 39.50 percent. Neurocrine Biosciences stock is EUR 128.00 on October 5, 2026, up 0.59 percent.
ad-hoc-news.de, 05.10.26 09:00 Uhr
NBIX, US64125C1099
Neurocrine names Eiry W. Roberts CMO and Neurocrine Biosciences ...
Second-quarter 2026 revenue reached USD 959.0 million. Neurocrine Biosciences stock costs EUR 127.33 on October 2, 2026 after EUR 125.15.
ad-hoc-news.de, 02.10.26 21:52 Uhr
NBIX, US64125C1099
Resilient Neurocrine Biosciences stock holds firm as Crenessity ...
Neurocrine Biosciences stock is trading in a firm range as investors weigh strong Crenessity sales growth against a premium valuation and updated revenue and EPS expectations ...
ad-hoc-news.de, 01.09.26 09:59 Uhr
